Cognition Therapeutics (CGTX) Live Share Price, Invest From India

Cognition Therapeutics Stock Performance

as on September 25, 2026 at 2:15 pm IST

Day's Low
Day's High
$0.93
Day's Price Range
$0.97
$0.95
2.19%
Downside
2.02%
Upside
52 Week's Low
52 Week's High
$0.55
52-Week Price Range
$2.05
$0.95
42.14%
Downside
115.61%
Upside

Cognition Therapeutics share price movements today

Previous Close: $0.95
Open: $0.97
Volume: 351.8K
Market Cap: $90.3M
Day's Low - High: $0.93 - $0.97
52 Week Low - High: $0.55 - $2.05

Cognition Therapeutics Historical Returns

1 Month Return: -7.69 %
3 Month Return: -15.86 %
1 Year Return: -24.54 %
3 Year Return: -27.42 %
5 Year Return: 0 %

Cognition Therapeutics Stock Fundamentals & Key Indicators

Check Cognition Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$90.3M

EPS (TTM)

-0.192

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.95

Industry PE ratio

-2.69

PEG Ratio

-0.030870840006208114

EBITDA

-16.6M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-50.17%

Cognition Therapeutics Stock Valuation

Track how Cognition Therapeutics P/E has moved over time to understand its valuation trends.

Cognition Therapeutics in the last 5 years

Overview
Trends

Lowest (-11.99x)

December 31, 2021

Today (-4.22x)

December 31, 2025

Industry (-2.69x)

December 31, 2025

Highest (80.43x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -4.22x

Cognition Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cognition Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Cognition Therapeutics	Buy	$90.3M	NA	-4.95	0.00%	0.00%
Moderna	Neutral	$72.7B	-54.71%	-22.82	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$130.9B	184.51%	29.81	86.04%	0.00%
Regeneron	Buy	$82.8B	24.59%	19.15	84.86%	0.46%

Stock Returns calculator for Cognition Therapeutics Stock including INR - Dollar returns

The Cognition Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Cognition Therapeutics investment value today

Current value as on today

₹81,553

Returns

-₹18,447

(-18.45%)

Returns from Cognition Therapeutics Stock

-₹24,540 (-24.54%)

Dollar Impact

₹6,093 (+6.09%)

Analyst Recommendation on Cognition Therapeutics Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Cognition Therapeutics. Average target price of $3.33

Cognition Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Cognition Therapeutics.

What analysts predicted

71.45%UPSIDE

Target Price

$3.33

Current Price

$0.9508

Analyzed by

1 Analysts

Target

$3.33

Cognition Therapeutics target price $3.33, a slight upside of 71.45% compared to current price of $0.9508. According to 1 analysts rating.

Indian Investors' Interest in Cognition Therapeutics Stock

Search interest for Cognition Therapeutics Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 26, 2026 to September 25, 2026

Change:-13% versus previous 30 day period

Cognition Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	-	-	-	-	0	-	0	-
Operating Income	-14	-14	-14	-10	-13	-13	-6	-13	-8	-7
EBITDA	-9	-6	-9	-7	-8	-6	-4	-3	-4	-3
Interest Expense	0	0	0	0	0	0	-	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-9	-7	-9	-7	-8	-6	-4	-3	-4	-3
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-9	-7	-9	-7	-8	-6	-4	-3	-4	-3
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Cognition Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-
Gross Profit	0	0	-	0	-	-	-
Operating Income	-17	-17	-28	-43	-50	-53	-47
EBITDA	-3	-5	-10	-21	-25	-33	-23
Interest Expense	1	1	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0
Income Before Tax	-4	-7	-11	-21	-25	-33	-23
Income Tax Expense	-	-	-	-22	-	-	-
Net Income	-6	-10	-11	0	-25	-33	-23
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Cognition Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-9	-7	-9	-7	-8	-6	-4	-3	-4	-3
Operating Cash Flow	-7	-5	-6	-8	-9	-5	-5	-3	-5	-3
Investing Cash Flow	-	0	-	0	-	-	-	0	-	0
Financing Cash Flow	11	0	0	11	1	0	33	0	0	6
Change in Cash	4	-6	-6	2	-8	-4	28	-2	-5	3

Cognition Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-4	-7	-11	-21	-25	-33	-23
Operating Cash Flow	-3	-3	-3	-18	-16	-28	-24
Investing Cash Flow	0	0	0	0	0	0	0
Financing Cash Flow	2	5	53	5	4	23	36
Change in Cash	0	2	49	-13	-11	-4	11

Mutual Funds that own Cognition Therapeutics Stock

Check out the Mutual Funds with significant holdings in Cognition Therapeutics.

Funds	Holdings	Shares Held
VANGUARD INDEX FUNDS	3.082437%	2931205
Fidelity Concord Street Trust	0.766202%	728611
SCHWAB CAPITAL TRUST	0.089322%	84940
VANGUARD VALLEY FORGE FUNDS	0.040786%	38785
VANGUARD INSTITUTIONAL INDEX FUNDS	0.033437%	31797

See all

Global Institutional Holdings in Cognition Therapeutics

Funds	Holdings
Vanguard	3.54%
VANGUARD INDEX FUNDS	3.08%
Fidelity Concord Street Trust	0.77%
iShares	0.29%
Kenneth Tropin	0.16%

See all

Insights on Cognition Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 98.5% return, outperforming this stock by 125.9%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 691.6% return, outperforming this stock by 716.1%
NEGATIVE IMPACT
Price Dip
In the last 7 days, CGTX stock has moved down by -8.6%

About Cognition Therapeutics

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

Organisation	Cognition Therapeutics
Headquarters	2500 Westchester Avenue, Purchase, NY, 10577, US
Industry	Biotechnology
CEO	Lisa Ricciardi
E-voting on shares	Click here to vote

Key Management of Cognition Therapeutics

Name	Title
Mr. Bobby Horn	Corporate Controller
Ms. Lisa Ricciardi	CEO, President & Director
Mr. John Brendan Doyle	Chief Financial Officer
Dr. Anthony O. Caggiano M.D., Ph.D.	Chief Medical Officer
Dr. Steven A. Weissman Ph.D.	VP & Head of CMC
Ms. Anita Cornet	Head of Quality

FAQs

What is Cognition Therapeutics share price today?

Cognition Therapeutics share price today is $0.95 as on September 25, 2026 at 8:45 am IST at the close of the market. Cognition Therapeutics share today touched a day high of $0.97 and a low of $0.93.

What is the 52 week high and 52 week low for Cognition Therapeutics share?

Cognition Therapeutics share touched a 52 week high of $2.05 on October 10, 2025 and a 52 week low of $0.55 on March 30, 2026. Cognition Therapeutics stock price today i.e. September 25, 2026 at 8:45 am IST is closed at $0.95,which is 53.62% down from its 52 week high and 72.84% up from its 52 week low.

What is Cognition Therapeutics's market capitalisation today?

Cognition Therapeutics market capitalisation is $0.00T as on September 25, 2026 at 8:45 am IST.

How to invest in Cognition Therapeutics Stock (CGTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cognition Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cognition Therapeutics Shares that will get you 1.5776 shares as per Cognition Therapeutics share price of $0.95 per share as on September 25, 2026 at 8:45 am IST.

What is the minimum amount required to buy Cognition Therapeutics Stock (CGTX) from India?

Indian investors can start investing in Cognition Therapeutics (CGTX) shares with as little as ₹95.945 or $1 (as of September 25, 2026 at 10:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹959.45 in Cognition Therapeutics stock (as per the Rupee-Dollar exchange rate as on September 25, 2026 at 10:38 am IST). Based on Cognition Therapeutics share’s latest price of $0.95 as on September 25, 2026 at 8:45 am IST, you will get 10.5175 shares of Cognition Therapeutics. Learn more about fractional shares .